Uniphar, a Dublin-based healthcare services group, reported a revenue increase of 11% in 2025, surpassing €3.1 billion as it entered 2026 with strong trading momentum. The company, which is listed on the Irish stock exchange, said its three main divisions all achieved growth, with the supply chain and retail arm showing the most significant increase. This performance was accompanied by a 7% rise in gross profit, driven by consistent growth across all divisions.

Divisions Deliver Strong Growth

According to the company’s annual results, the pharma and medtech divisions delivered organic gross profit growth of 15.5% and 10.5% respectively. The supply chain and retail division also showed growth, albeit at a slower rate of 4.2%.

Chief Executive Ger Rabbette expressed satisfaction with the results, stating, ‘I am pleased with the results the group delivered in 2025, achieving our fastest rate of organic gross profit growth since IPO at 8.9 per cent, alongside adjusted earnings per share growth of 21 per cent.’ Rabbette emphasized the successful execution of the company’s strategy across all divisions and its ability to scale and generate sustainable growth.

The company’s gross margin declined slightly, from 15.4% to 14.9% in the year, despite the overall growth in revenue and profit. However, this was offset by the continued strong performance of its core divisions.

Dividend Increase and Future Targets

The directors proposed a dividend of €3.4 million, or 1.3 cent per ordinary share, for the year. This brings the total dividend for the year to €5.2 million, or 2 cent per share, representing an increase of 5.2% compared to the previous year. The company also noted that adjusted earnings per share grew by 21% to 24.8 cent, marking a significant increase in profitability.

Rabbette added, ‘Over the past six years, we have delivered excellent compound annual adjusted earnings per share growth of 16 per cent. These results reflect the successful execution of our strategy across all divisions and our continued ability to scale and generate sustainable growth.’

Looking ahead, Uniphar stated it remains ‘well positioned’ to achieve continued organic gross profit growth in each division in line with its medium-term targets. The company is confident of delivering on current market expectations for the full year and remains focused on achieving its target of €200 million in earnings before interest, taxes, depreciation, and amortisation (EBITDA) by 2028. At least 80% of this growth is expected to be delivered organically.

The company said it has entered 2026 with ‘strong trading momentum’ and is doing business in line with expectations. With the continued growth in its core divisions and the successful execution of its strategy, Uniphar is positioned to deliver on its long-term goals and maintain its strong financial performance.

As the healthcare sector continues to evolve, Uniphar’s ability to adapt and deliver consistent growth will be critical in maintaining its competitive edge. The company’s strong performance in 2025 sets a solid foundation for future success and reinforces its position as a key player in the global healthcare services market.